Q4 2025 Integra Lifesciences Holdings Corp Earnings Call Transcript
Key Points
- Integra Lifesciences Holdings Corp (IART) reported fourth-quarter 2025 revenue of $435 million and adjusted earnings per share of $0.83, both above the midpoint of their guidance range.
- The company advanced its In-China-For-China strategy by completing submission of initial regulatory requirements, reinforcing its foundation for future growth.
- IART launched several new products, including the MAYFIELD Ghost in the US and received an expanded indication for CUSA Clarity in cardiac surgery.
- The company improved supply reliability and enhanced execution capabilities, leading to significant outcomes in key supply chain resiliency efforts.
- IART welcomed six new leaders to its executive leadership team, adding depth and capabilities that support its focus on quality, execution, and long-term growth.
- Full-year 2025 revenue showed a 0.7% organic decline, impacted by quality remediation work and supply constraints.
- Gross margin for the full year was down 260 basis points year over year, reflecting tariffs, supply pressures, and incremental costs associated with compliance.
- Fourth-quarter revenue declined by 1.7% on a reported basis and 2.5% organically, reflecting a strong prior year comparison.
- Free cash flow was negative $5.4 million in the fourth quarter, driven by restructuring costs and increased working capital.
- The Tissue Technologies segment saw a 12.8% decline in revenues, impacted by remediation efforts for MediHoney and a tough comparison with the previous year's record IntegraSkin revenue.
Good day and welcome to the Integra LifeSciences fourth-quarter 2025 financial results. (Operator Instructions) This call may be recorded.
I would like to turn the call over to Chris Ward, Senior Director of Investor Relations. Please go ahead.
Good morning, thank you for joining Integra LifeSciences fourth-quarter 2025 earnings conference call. With me on the call are Mojdeh Poul, President and Chief Executive Officer; and Lea Knight, Chief Financial Officer.
Earlier this morning, we issued a press release announcing our fourth-quarter 2025 financial results. The release and corresponding earnings presentation, which we'll reference during the call, are available at integralife.com under Investors, Events & Presentations, in the filing fourth-quarter 2025 earnings call presentation.
Before we begin, I want to remind you that many of the statements made during this call may be considered forward-looking. Factors that could cause actual results to differ
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
